Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.

Low α2-macroglobulin, impaired fibrinolysis up risk of asthma exacerbation

14 Sep 2017

Lower plasma levels of α2-macroglobulin and impaired fibrinolysis appear to increase the risk of asthma exacerbations, a new study has shown.

In the study sample of 157 patients with asthma, 198 severe asthma exacerbations were recorded, corresponding to 64 events per year. These were observed in 34 percent (n=53) of the patients, of whom 33 had at least three complication events.

Those who experienced exacerbations were significantly older (p=0.004), had longer asthma duration (p=0.006) and worse asthma control (p=0.02). Those with exacerbations also showed significantly lower forced expiratory volumes in 1 second (p=0.01) compared with controls.

Interestingly, in those who experienced at least one exacerbation, clot lysis time (CLT) was significantly longer (p=0.038) and α2-macroglobulin levels were significantly lower (p=0.04) after controlling for potential confounders.

Even in moderate and severe asthmatics (n=47), at least one case of asthma exacerbation was association with significantly higher CLT (p=0.002) and lower α2-macroglobulin (p=0.04).

In multiple logistic regression analysis, asthma duration (odds ratio [OR], 1.037; 95 percent CI, 1.011 to 1.065; p=0.006), asthma control test (OR, 0.971; 0.905 to 0.999; p=0.046), CLT (OR, 1.007; 1.001 to 1.013; p=0.049) and α2-macroglobulin (OR, 0.938; 0.886 to 0.992; p=0.025) were all identified as independent predictors of exacerbated asthmatic events.

The most important factors that contribute to the risk of asthma exacerbation were severe asthma (relative risk [RR], 1.55; 1.19 to 2.03; p<0.0001), oral corticosteroids at baseline (RR, 2.15; 1.49 to 3.11; p<0.0001) and gastroesophageal reflux disease (RR, 2.5; 1.7 to 3.61; p<0.0001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.